Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eukaryotic-like gephyrin and cognate membrane receptor coordinate corynebacterial cell division and polar elongation.

bioRxiv : the preprint server for biology·2023
Same author

Advanced Quantification Methods To Improve the 18b Dormancy Model for Assessing the Activity of Tuberculosis Drugs <i>In Vitro</i>.

Antimicrobial agents and chemotherapy·2020
Same author

Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2018
Same author

Mechanistic insight into mycobacterial MmpL protein function.

Molecular microbiology·2015
Same author

Genome-wide re-sequencing of multidrug-resistant Mycobacterium leprae Airaku-3.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2014
Same author

Transcriptional regulation of lipid homeostasis in mycobacteria.

Molecular microbiology·2010

Related Experiment Video

Updated: Jul 10, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Towards new tuberculosis drugs.

S T Cole1, P M Alzari

  • 1Global Health Institute, Ecole Polytechnique Fédérale de Lausanne, AI 3151, Station 15, CH-1015 Lausanne, Switzerland. stewart.cole@epfl.ch

Biochemical Society Transactions
|October 25, 2007
PubMed
Summary
This summary is machine-generated.

New tuberculosis drugs are urgently needed to shorten treatment duration. Recent research focuses on novel compounds to improve upon the Directly Observed Therapy Short Course (DOTS) regimen.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Related Experiment Videos

Last Updated: Jul 10, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Area of Science:

  • Drug discovery and development
  • Infectious diseases
  • Tuberculosis research

Background:

  • Tuberculosis (TB) remains a significant global health threat, necessitating improved therapeutic strategies.
  • Current TB treatment, Directly Observed Therapy Short Course (DOTS), requires a lengthy duration of 6 months.
  • Insufficient funding for discovery research poses a challenge to developing novel anti-TB agents.

Purpose of the Study:

  • To review advancements in the discovery and development of new anti-tuberculosis lead compounds.
  • To highlight progress made in the last five years towards reducing TB treatment duration.
  • To identify successes and persistent challenges in developing novel TB drugs.

Main Methods:

  • Literature review of recent scientific publications (last 5 years) on tuberculosis drug discovery.
  • Analysis of reported progress in identifying and developing new lead compounds for TB treatment.
  • Synthesis of information on therapeutic advancements and associated challenges.

Main Results:

  • Significant efforts have been directed towards finding compounds that can shorten TB treatment.
  • Progress has been made in identifying potential new drug candidates.
  • Challenges remain in drug development, including funding and efficacy.

Conclusions:

  • Despite challenges, advancements in finding new tuberculosis drugs offer hope for shorter treatment regimens.
  • Continued research and investment are crucial to overcome obstacles in TB drug development.
  • The development of novel compounds is key to improving upon current tuberculosis treatment protocols.